Physician profile
Penny Heinrich
NPI 1083804546
$1,303.92
in general payments reported to CMS, 2019-2025
17 companies · $34.83 in 2025
The $34.83 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,006 · 2020: $62.08 · 2021: $66.14 · 2022: $47.40 · 2023: $87.04 · 2025: $34.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $167.82 | 2019 | |
| Boston Scientific Corporation | $164.97 | 2019-2021 | |
| Genentech USA, INC. | $163.92 | 2019 | |
| Merck Sharp & Dohme LLC | $163.06 | 2019 | |
| Celgene Corporation | $155.78 | 2019-2023 | Reblozyl |
| Tersera Therapeutics LLC | $142.28 | 2019 | |
| Puma Biotechnology, INC. | $64.88 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $56.27 | 2019 | |
| Novartis Pharmaceuticals Corporation | $55.16 | 2019 | |
| Genzyme Corporation | $31.07 | 2023-2025 | |
| Daiichi Sankyo INC. | $27.88 | 2019 | |
| Amgen INC. | $27.65 | 2019 | |
| Astellas Pharma US INC | $19.99 | 2025 | Vyloy |
| Janssen Biotech, INC. | $18.65 | 2019 | |
| Pfizer INC. | $17.51 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $15.07 | 2019 | |
| Gilead Sciences, INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Penny Heinrich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.